Current Report Filing (8-k)
August 09 2019 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2019
ENDOLOGIX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-28440
|
|
68-0328265
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
2 Musick, Irvine, CA
|
|
92618
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (949)
595-7200
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☒
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
ELGX
|
|
The Nasdaq Stock Market, LLC
|
Item 8.01 Other Events.
On August 9, 2019, Endologix, Inc. (the Company) announced to certain eligible employees and members of the Board of Directors
(Eligible Participants) the approval of a voluntary,
one-time
stock option for stock option exchange program (the Option Exchange Program) for Eligible Participants to exchange certain
underwater stock options for a lesser number of new stock options (the New Stock Options). The number of New Stock Options will be determined using exchange ratios designed to result in the New Stock Options having approximately the same
value, from an accounting standpoint, as the stock options that are exchanged.
The Option Exchange Program was previously approved by the
Board of Directors of the Company and subsequently approved by the Companys stockholders at the 2019 Annual Meeting of Stockholders held on August 5, 2019.
Attached as Exhibit 99.1 is an email communication (the Communication to Eligible Participants) regarding the proposed Option
Exchange Program that was sent to Eligible Participants on August 9, 2019. The Communication to Eligible Participants does not constitute an offer to holders of the Companys outstanding stock options to exchange those stock options for
New Stock Options.
The Option Exchange Program has not yet commenced and will only be made pursuant to the terms and conditions set forth
in the Tender Offer Statement on Schedule TO, including the Offer to Exchange, and other related materials filed with the Securities and Exchange Commission (the SEC) and sent to eligible option holders. At the time the Option Exchange
Program begins, the Company will provide eligible option holders with written materials explaining the terms of the Option Exchange Program. Persons who are eligible to participate in the Option Exchange Program should read these written materials
carefully when they become available because they will contain important information about the Option Exchange Program. The Company will also file these written materials with the SEC as part of a Tender Offer Statement upon commencement of the
Option Exchange Program. The Companys stockholders and eligible option holders will be able to obtain these tender offer documents, as well as other documents that the Company files with the SEC, free of charge at www.sec.gov or by contacting
the Companys Corporate Secretary at Endologix, Inc., 2 Musick, Irvine, California 92618,
(949-595-7200).
In addition, eligible option holders may obtain free
copies of the tender offer documents by visiting the OEP website located at: http://www.endologix.compintelligence.com.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ENDOLOGIX, INC.
|
|
|
|
|
Date: August 9, 2019
|
|
|
|
|
|
/s/ Vaseem Mahboob
|
|
|
|
|
|
|
Vaseem Mahboob
|
|
|
|
|
|
|
Chief Financial Officer
|
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024